Urologic Survey

Re: Collagenase Clostridium Histolyticum for the Treatment of Peyronie’s Disease: A Prospective Italian Multicentric Study


  • Emre Bakırcıoğlu

J Urol Surg 2019;6(1):84-84


Collagenase clostridium histolyticum (CCH) is the first licensed drug for the treatment of Peyronie’s diease and is indicated in patients with palpable plaque and a curvature deformity of ≥30°. This multicentiric study focused on the results of CCH injections performed in five centers in Italy. A total of 135 patients have completed the treatment with three injections of CCH (0.9 mg) given at 4-week intervals in combination with home modeling activities including stretching and vacuum device use on a daily basis. An improvement in the angle of curvature was recorded in 94.8% of the patients by a mean of 19° (0-40°) or 42.9% (0-67%) from baseline (p<0.001). There was a statistically significant improvement in all international index of erectile function and physician data query questionnaires subdomains. This prospective multicentric study confirms that the three-injection protocol is effective enough to achieve a good result and to minimize the cost of the treatment.